Trials / Completed
CompletedNCT02469155
A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment
A Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-Center Study to Assess the Antipsychotic Efficacy of ITI-007 After 6 Weeks of Treatment in Patients With Schizophrenia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 696 (actual)
- Sponsor
- Intra-Cellular Therapies, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The study will evaluate the antipsychotic efficacy of ITI-007 in a randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study in patients diagnosed with schizophrenia having an acute exacerbation of psychosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ITI-007 | |
| DRUG | Risperidone | |
| DRUG | Placebo |
Timeline
- Start date
- 2015-06-01
- Primary completion
- 2016-08-01
- Completion
- 2016-08-01
- First posted
- 2015-06-11
- Last updated
- 2025-10-02
- Results posted
- 2025-10-02
Locations
11 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02469155. Inclusion in this directory is not an endorsement.